Shi Dan, He Ming-Yuan, Zhao Zhi-Peng, Wu Ning, Zhao Hong-Fu, Xu Zhi-Jian, Cheng Guang-Hui
Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, China E-mail :
Asian Pac J Cancer Prev. 2015;16(9):3945-9. doi: 10.7314/apjcp.2015.16.9.3945.
For brachytherapy of cervical cancer, applicator shifts can not be avoided. The present investigation concerned Utrecht interstitial applicator shifts and their effects on organ movement and DVH parameters during 3D CT-based HDR brachytherapy of cervical cancer.
After the applicator being implanted, CT imaging was achieved for oncologist contouring CTVhr, CTVir, and OAR, including bladder, rectum, sigmoid colon and small intestines. After the treatment, CT imaging was repeated to determine applicator shifts and OARs movements. Two CT images were matched by pelvic structures. In both imaging results, we defined the tandem by the tip and the base as the marker point, and evaluated applicator shift, including X, Y and Z. Based on the repeated CT imaging, oncologist contoured the target volume and OARs again. We combined the treatment plan with the repeated CT imaging and evaluated the change range for the doses of CTVhr D90, D2cc of OARs.
The average applicator shift was -0.16 mm to 0.10 mm for X, 1.49 mm to 2.14 mm for Y, and 1.9 mm to 2.3 mm for Z. The change of average physical doses and EQD2 values in Gyα/β range for CTVhr D90 decreased by 2.55 % and 3.5 %, bladder D2cc decreased by 5.94 % and 8.77 %, rectum D2cc decreased by 2.94 % and 4 %, sigmoid colon D2cc decreased by 3.38 % and 3.72 %, and small intestines D2cc increased by 3.72 % and 10.94 %.
Applicator shifts and DVH parameter changes induced the total dose inaccurately and could not be ignored. The doses of target volume and OARs varied inevitably.
对于宫颈癌近距离放疗,施源器移位难以避免。本研究关注乌得勒支间质施源器移位及其在基于三维CT的宫颈癌高剂量率近距离放疗期间对器官运动和剂量体积直方图(DVH)参数的影响。
施源器植入后,进行CT成像,以便肿瘤医生勾勒高危临床靶区(CTVhr)、低危临床靶区(CTVir)和危及器官(OAR),包括膀胱、直肠、乙状结肠和小肠。治疗后,重复进行CT成像以确定施源器移位和OAR的运动。通过骨盆结构对两张CT图像进行匹配。在两次成像结果中,我们将施源器的尖端和底部定义为串联标记点,并评估施源器移位,包括X、Y和Z方向。基于重复的CT成像,肿瘤医生再次勾勒靶区体积和OAR。我们将治疗计划与重复的CT成像相结合,并评估CTVhr D90剂量、OAR的D2cc剂量的变化范围。
X方向施源器平均移位为-0.16 mm至0.10 mm,Y方向为1.49 mm至2.14 mm,Z方向为1.9 mm至2.3 mm。CTVhr D90在Gyα/β范围内的平均物理剂量和等效剂量(EQD2)值变化分别降低了2.55%和3.5%,膀胱D2cc分别降低了5.94%和8.77%,直肠D2cc分别降低了2.94%和4%,乙状结肠D2cc分别降低了3.38%和3.72%,小肠D2cc分别增加了3.72%和10.94%。
施源器移位和DVH参数变化会导致总剂量不准确,不容忽视。靶区体积和OAR的剂量不可避免地会发生变化。